metricas
covid
Buscar en
Clínica e Investigación en Arteriosclerosis
Toda la web
Inicio Clínica e Investigación en Arteriosclerosis Relación entre la infección por Helicobacter pylori y el perfil lipídico: efe...
Información de la revista
Vol. 15. Núm. 1.
Páginas 16-20 (enero 2003)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 15. Núm. 1.
Páginas 16-20 (enero 2003)
Acceso a texto completo
Relación entre la infección por Helicobacter pylori y el perfil lipídico: efecto del tratamiento erradicador
The relationship between helicobacter pylori infection and lipid profile: the effect of erradicative therapy
Visitas
5790
J.M. Mostazaa,
Autor para correspondencia
jmostazap@medynet.com

Correspondencia: Unidad de Arteriosclerosis. Hospital Carlos III. C/ Sinesio Delgado, 10. 28029 Madrid. España.
, R. Peñaa, C. Lahoza, C. Torob, M. Baquerob, M.D. Gutiérrezc, J. Gómez Geriquec
a Unidad de Arteriosclerosis del Hospital Carlos III. Madrid
b Servicio de Microbiología. Hospital Carlos III . Madrid
c Servicio de Bioquímica. Fundación Jiménez Díaz. Madrid. España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas

Se trata de un estudio retrospectivo, realizado a 137 pacientes con infección activa por Helicobacter pylori y a 37 no infectados, en el que se ha evaluado la concentración de lípidos y lipoproteínas y su respuesta después del tratamiento erradicador. Los pacientes con infección presentaron una concentración de colesterol total y triglicéridos más elevada que los no infectados (220 frente a 200 mg/dl; p = 0,027 y 98 frente a 71 mg/dl; p = 0,008, respectivamente). La prevalencia de serología positiva a marcadores de mayor virulencia (CagA y VacA) no se asoció con alteraciones más desfavorables en el perfil lipídico. La erradicación de la infección se acompañó de un incremento en la concentración de cHDL (de 52,3 a 56,4 mg/dl; p = 0,001).

Palabras clave:
Helicobacter pylori
Colesterol
Infección

In a retrospective study the lipid profile of 137 patients with active infection and 37 with no infection by Helicobacter pylori was analyzed before and after eradicative therapy. Infected patients presented higher total cholesterol and triglyceride concentrations (220 vs 200 mg/dl, p = 0.027, 98 vs 71 mg/dl, p = 0.008, respectively) than not infected.

The prevalence of positive serological tests showing higher aggressive infection (CagA y VacA) was not associated with changes in lipid profile abnormalities. Eradicative therapy was associated with an increase of HDL-cholesterol concentration (from 52.3 mg/dl to 56.4 mg/dl, p = 0.001).

Key words:
Helicobacter pylori
Cholesterol
Infection
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Danesh, R. Collins, R. Peto.
Chronic infections and coronary heart disease: is there a link?.
[2.]
J.L. Mehta, T.G. Saldeen, K. Rand.
Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease.
J Am Coll Cardiol, 31 (1998), pp. 1217-1225
[3.]
V. Pasceri, G. Cammarota, G. Patti, L. Cuoco, A. Gasbarrini, R.L. Grillo, et al.
Association of virulent Helicobacter pylori strains with ischemic heart disease.
Circulation, 97 (1998), pp. 1675-1679
[4.]
P. Patel, M.A. Mendall, D. Carrington, D.P. Strachan, E. Leatham, N. Molineaux, et al.
Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors.
Bmj, 311 (1995), pp. 711-714
[5.]
P. Pieniazek, E. Karczewska, A. Duda, W. Tracz, M. Pasowicz, S.J. Konturek.
Association of Helicobacter pylori infection with coronary heart disease.
J Physiol Pharmacol, 50 (1999), pp. 743-751
[6.]
N.J. Wald, M.R. Law, J.K. Morris, A.M. Bagnall.
Helicobacter pylori infection and mortality from ischaemic heart disease: negative result from a large, prospective study.
Bmj, 315 (1997), pp. 1199-1201
[7.]
A.R. Folsom, F.J. Nieto, P. Sorlie, L.E. Chambless, D.Y. Graham.
Helicobacter pylori seropositivity and coronary heart disease incidence. Atherosclerosis Risk In Communities (ARIC) Study Investigators.
Circulation, 98 (1998), pp. 845-850
[8.]
P.H. Whincup, M.A. Mendall, I.J. Perry, D.P. Strachan, M. Walker.
Prospective relations between Helicobacter pylori infection, coronary heart disease, and stroke in middle aged men.
Heart, 75 (1996), pp. 568-572
[9.]
D.P. Strachan, M.A. Mendall, D. Carrington, B.K. Butland, J.W. Yarnell, P.M. Sweetnam, et al.
Relation of Helicobacter pylori infection to 13-year mortality and incident ischemic heart disease in the Caerphilly prospective heart disease study.
Circulation, 98 (1998), pp. 1286-1290
[10.]
T.E. Strandberg, R.S. Tilvis, M. Vuoristo, M. Lindroos, T.U. Kosunen.
Prospective study of Helicobacter pylori seropositivity and cardiovascular diseases in a general elderly population.
Bmj, 314 (1997), pp. 1317-1318
[11.]
A. Laurila, A. Bloigu, S. Nayha, J. Hassi, M. Leinonen, P. Saikku.
Association of Helicobacter pylori infection with elevated serum lipids.
Atherosclerosis, 142 (1999), pp. 207-210
[12.]
S. Niemela, T. Karttunen, T. Korhonen, E. Laara, R. Karttunen, M. Ikaheimo, et al.
Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations?.
Heart, 75 (1996), pp. 573-575
[13.]
G.Y. Lip, A.D. Blann, D.G. Beevers.
Helicobacter pylori seropositivity, lipid concentrations and haemostatic factors.
J Intern Med, 248 (2000), pp. 354-355
[14.]
L.J. Murray, K.B. Bamford, D.P. O’Reilly, E.E. McCrum, A.E. Evans.
Helicobacter pylori infection: relation with cardiovascular risk factors, ischaemic heart disease, and social class.
Br Heart J, 74 (1995), pp. 497-501
[15.]
R.K. Scragg, A. Fraser, P.A. Metcalf.
Helicobacter pylori seropositivity and cardiovascular risk factors in a multicultural workforce.
J Epidemiol Community Health, 50 (1996), pp. 578-579
[16.]
M.A. Mendall, P. Patel, L. Ballam, D. Strachan, T.C. Northfield.
C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study.
Bmj, 312 (1996), pp. 1061-1065
[17.]
A. Hoffmeister, D. Rothenbacher, G. Bode, K. Persson, W. Marz, M.A. Nauck, et al.
Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile.
Arterioscler Thromb Vasc Biol, 21 (2001), pp. 427-432
[18.]
A. Domingo Salvany, J. Marcos Alonso.
Propuesta de un indicador de clase social basado en la ocupación.
Gac Sanit, 3 (1989), pp. 320-326
[19.]
F. Blasi, M.L. Ranzi, M. Erba, P. Tarsia, R. Raccanelli, L. Fagetti, et al.
No evidence for the presence of Helicobacter pylori in atherosclerotic plaques in abdominal aortic aneurysm specimens.
Atherosclerosis, 126 (1996), pp. 339-340
[20.]
F. Blasi, F. Denti, M. Erba, R. Cosentini, R. Raccanelli, A. Rinaldi, et al.
Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms.
J Clin Microbiol, 34 (1996), pp. 2766-2769
[21.]
P.W. Radke, S. Merkelbach-Bruse, B.J. Messmer, J. vom Dahl, H. Dorge, A. Naami, et al.
Infectious agents in coronary lesions obtained by endatherectomy: pattern of distribution, coinfection, and clinical findings.
Coron Artery Dis, 12 (2001), pp. 1-6
[22.]
S.F. Ameriso, E.A. Fridman, R.C. Leiguarda, G.E. Sevlever.
Detection of Helicobacter pylori in human carotid atherosclerotic plaques.
Stroke, 32 (2001), pp. 385-391
[23.]
B. Farsak, A. Yildirir, Y. Akyon, A. Pinar, M. Oc, E. Boke, et al.
Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR.
J Clin Microbiol, 38 (2000), pp. 4408-4411
[24.]
N. Rifai, P.M. Ridker.
High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease.
Clin Chem, 47 (2001), pp. 403-411
[25.]
F. Parente, V. Imbesi, C. Cucino, G. MacOni, U. Russo, P.G. Duca, et al.
Helicobacter pylori CagA seropositivity does not influence inflammatory parameters, lipid concentrations and haemostatic factors in healthy individuals.
J Intern Med, 247 (2000), pp. 213-217
[26.]
J. Danesh, R. Peto.
Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies.
Bmj, 316 (1998), pp. 1130-1132
[27.]
F. Megraud.
How should Helicobacter pylori infection be diagnosed?.
Gastroenterology, 113 (1997), pp. S93-S98
[28.]
I. Hardardottir, C. Grunfeld, K.R. Feingold.
Effects of endotoxin and cytokines on lipid metabolism.
Curr Opin Lipidol, 5 (1994), pp. 207-215
[29.]
M.J. Blaser, G.I. Perez-Perez, H. Kleanthous, T.L. Cover, R.M. Peek, P.H. Chyou, et al.
Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach.
Cancer Res, 55 (1995), pp. 2111-2115
[30.]
W. Tee, J.R. Lambert, B. Dwyer.
Cytotoxin production by Helicobacter pylori from patients with upper gastrointestinal tract diseases.
J Clin Microbiol, 33 (1995), pp. 1203-1205
[31.]
G. Torgano, R. Cosentini, C. Mandelli, R. Perondi, F. Blasi, G. Bertinieri, et al.
Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease.
Circulation, 99 (1999), pp. 1555-1559
[32.]
D.A. de Luis, A. Garcia Avello, M.A. Lasuncion, R. Aller, C. Martin de Argila, D. Boixeda de Miquel, et al.
Improvement in lipid and haemostasis patterns after Helicobacter pylori infection eradication in type 1 diabetic patients.
Clin Nutr, 18 (1999), pp. 227-231
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.arteri.2024.10.004
No mostrar más